Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + atezolizumab versus second novel hormonal therapy in metastatic castration-resistant prostate cancer
2024-516481-11-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of cabozantinib, atezolizumab, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Exelixis, Inc. Primary endpoints: Progression-free survival and Overall survival. Planned start Sep 2020; status: authorised.
02
Drugs
cabozantinibatezolizumababirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-516481-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516481-11-00.